Globus Medical Total Liabilities 2010-2023 | GMED

Globus Medical total liabilities from 2010 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Globus Medical total liabilities for the quarter ending March 31, 2023 were $0.235B, a 10.07% increase year-over-year.
  • Globus Medical total liabilities for 2022 were $0.23B, a 6.43% increase from 2021.
  • Globus Medical total liabilities for 2021 were $0.216B, a 24.65% increase from 2020.
  • Globus Medical total liabilities for 2020 were $0.173B, a 33.61% increase from 2019.
Globus Medical Annual Total Liabilities
(Millions of US $)
2022 $230
2021 $216
2020 $173
2019 $130
2018 $115
2017 $111
2016 $96
2015 $119
2014 $118
2013 $94
2012 $61
2011 $47
2010 $38
2009 $0
Globus Medical Quarterly Total Liabilities
(Millions of US $)
2023-03-31 $235
2022-12-31 $230
2022-09-30 $212
2022-06-30 $216
2022-03-31 $213
2021-12-31 $216
2021-09-30 $192
2021-06-30 $191
2021-03-31 $175
2020-12-31 $173
2020-09-30 $125
2020-06-30 $129
2020-03-31 $116
2019-12-31 $130
2019-09-30 $113
2019-06-30 $103
2019-03-31 $99
2018-12-31 $115
2018-09-30 $97
2018-06-30 $97
2018-03-31 $101
2017-12-31 $111
2017-09-30 $102
2017-06-30 $90
2017-03-31 $92
2016-12-31 $96
2016-09-30 $92
2016-06-30 $90
2016-03-31 $91
2015-12-31 $119
2015-09-30 $127
2015-06-30 $122
2015-03-31 $130
2014-12-31 $118
2014-09-30 $93
2014-06-30 $90
2014-03-31 $97
2013-12-31 $94
2013-09-30 $76
2013-06-30 $76
2013-03-31 $65
2012-12-31 $61
2012-09-30 $52
2012-06-30 $46
2012-03-31 $53
2011-12-31 $47
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $38
2009-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $5.519B $0.759B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $200.336B 24.71
Edwards Lifesciences (EW) United States $51.668B 34.09
Alcon (ALC) Switzerland $38.531B 34.94
STERIS (STE) Ireland $19.969B 24.66
Fresenius Medical Care AG KGaA (FMS) Germany $12.634B 14.07
Penumbra (PEN) United States $12.021B 766.44
Teleflex (TFX) United States $10.964B 17.62
Glaukos (GKOS) United States $2.836B 0.00
Integer Holdings (ITGR) United States $2.750B 20.81
Paragon 28 (FNA) United States $1.497B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.144B 14.77
Nevro (NVRO) United States $0.982B 0.00
Artivion (AORT) United States $0.604B 369.25